Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 76Neoplasm Metastasis 12Neoplasms 10Neoplasms by Site 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Breast Diseases 3Recurrence 2Kidney Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma 1

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × palbociclib × Clear all
NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NiKang Therapeutics, Inc.

Phase 2 Terminated
18 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡